Primary navigation

    Juxtapid

    Drug - Juxtapid [Aegerion Pharmaceuticals, Inc.]

    June 2013

    Therapeutic area - Cardiovascular

    Approval criteria

    • Patient is greater than 18 years of age AND
    • Patient has a diagnosis of homozygous familial hypercholesterolemia (HoFH) AND
    • Baseline liver function tests have been completed AND
    • Patient has tried and failed or is not a candidate for LDL-apheresis AND
    • Female patients have had a pregnancy test and a confirmed negative result

    Quantity limit

    • 5 mg = 34
    • 10 mg = 34
    • 20 mg = 102

    Background information

    JUXTAPID is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top